- About EUPATI
- EUPATI News
- EUPATI Training Course
- EUPATI Events
- EUPATI Glossary
- Subscribe to Newsletter
- File Download
- Search this site
- Contact us
- File Download
- European Patients’ Academy Blog
The consortium project "European Patients‘ Academy on Therapeutic Innovation" (EUPATI), funded by the Innovative Medicines Initiative, will provide scientifically reliable, objective, comprehensive information to patients on medicines research and development. It will increase the capacities and capabilities of well-informed patients and patient organisations to be effective advocates and advisors in medicines research, e.g. in clinical trials, with regulatory authorities and in ethics committees. More about the Patients' Academy
Our new weekly blog is for you to get to know us better. But really. We’re going to tell you not only why we believe in patient engagement at all levels of health care systems but why it’s in everyone’s best interest to know more about taking better care of themselves by knowing more about the medicines research process, and how it directly connects to them. We have a Communications Team of 11 people, each of whom will talk to you about something intimate for them, hopefully something inspiring for you.
Reports and articles to come soon (in the meantime, more videos)!
See the outline of those sessions here:
While patient-centric approaches to research and development are gaining in popularity, another challenge is starting to present itself: how can patients engage with researchers in such a way that they work more as partners? In its article "Training on trials: Patients taught the language of drug development", the jounral Nature Medicine reports about EUPATI and how it empowers patients to be advocates in medicines R&D. Read the article here.
We are now halfway through our 5-year journey on making an information resource that educates patient advocates, patients and the broader public about how medicines research and development works, and your part in it.
From theory to reality.